RecruitingPhase 2NCT06778031

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

An Open, Multicenter Phase II Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrollment

54 participants

Start Date

Feb 26, 2025

Study Type

INTERVENTIONAL

Conditions

HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

Summary

This study is an open, multicenter Phase II clinical trial to evaluate the efficacy and safety of the SHR-A1811 combination in HER2 positive patients with locally advanced or metastatic biliary tract cancer.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SHR-1316, a drug called SHR-8068, and others for people with her2-positive locally advanced or metastatic biliary tract cancer. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSHR-A1811

SHR-A1811.

DRUGSHR-1316

SHR-1316.

DRUGSHR-8068

SHR-8068.

Locations(2)

Affiliated Cancer Hospital of Harbin Medical University

Harbin, Heilongjiang, China

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06778031